Egle Therapeutics, based in Paris, is developing advanced immunotherapies for cancer and autoimmune diseases. Unlike traditional treatments, which often have severe side effects and limited effectiveness, Egle's approach aims to offer better outcomes with fewer side effects. By targeting immune system mechanisms, Egle can potentially transform patient experiences and increase survival rates. Their B2B model, supported by investors like Bioqube Ventures, positions them to form strategic partnerships and secure resources for growth, making them a promising contender in health tech.